These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 24812664)

  • 1. Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction.
    Bauer CA; Kim EY; Marangoni F; Carrizosa E; Claudio NM; Mempel TR
    J Clin Invest; 2014 Jun; 124(6):2425-40. PubMed ID: 24812664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consequences of double negative regulatory T cell and antigen presenting cell interaction on immune response suppression.
    Ford McIntyre MS; Gao JF; Li X; Naeini BM; Zhang L
    Int Immunopharmacol; 2011 May; 11(5):597-603. PubMed ID: 21109036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced suppression of polyclonal CD8
    Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
    J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells.
    Dilek N; Poirier N; Hulin P; Coulon F; Mary C; Ville S; Vie H; Clémenceau B; Blancho G; Vanhove B
    PLoS One; 2013; 8(12):e83139. PubMed ID: 24376655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirement of Treg-intrinsic CTLA4/PKCη signaling pathway for suppressing tumor immunity.
    Pedros C; Canonigo-Balancio AJ; Kong KF; Altman A
    JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique properties of thymic antigen-presenting cells promote epigenetic imprinting of alloantigen-specific regulatory T cells.
    Garg G; Nikolouli E; Hardtke-Wolenski M; Toker A; Ohkura N; Beckstette M; Miyao T; Geffers R; Floess S; Gerdes N; Lutgens E; Osterloh A; Hori S; Sakaguchi S; Jaeckel E; Huehn J
    Oncotarget; 2017 May; 8(22):35542-35557. PubMed ID: 28415767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells.
    Xiang J; Huang H; Liu Y
    J Immunol; 2005 Jun; 174(12):7497-505. PubMed ID: 15944248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIGIT predominantly regulates the immune response via regulatory T cells.
    Kurtulus S; Sakuishi K; Ngiow SF; Joller N; Tan DJ; Teng MW; Smyth MJ; Kuchroo VK; Anderson AC
    J Clin Invest; 2015 Nov; 125(11):4053-62. PubMed ID: 26413872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
    Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity.
    Chen X; Du Y; Huang Z
    Immunol Lett; 2012; 148(1):83-9. PubMed ID: 23000301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD28-CD80 interactions control regulatory T cell motility and immunological synapse formation.
    Thauland TJ; Koguchi Y; Dustin ML; Parker DC
    J Immunol; 2014 Dec; 193(12):5894-903. PubMed ID: 25355918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines.
    Chakraborty NG; Li L; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
    J Immunol; 1999 May; 162(9):5576-83. PubMed ID: 10228040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
    Gao Q; Qiu SJ; Fan J; Zhou J; Wang XY; Xiao YS; Xu Y; Li YW; Tang ZY
    J Clin Oncol; 2007 Jun; 25(18):2586-93. PubMed ID: 17577038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen.
    Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
    J Immunol; 2003 Oct; 171(8):4121-30. PubMed ID: 14530334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
    Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
    J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
    Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
    Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced CTL motility and activity in avascular tumor areas.
    Manaster Y; Shipony Z; Hutzler A; Kolesnikov M; Avivi C; Shalmon B; Barshack I; Besser MJ; Feferman T; Shakhar G
    Cancer Immunol Immunother; 2019 Aug; 68(8):1287-1301. PubMed ID: 31253998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.